Atul R. Mahableshwarkar, M.D., DFAPA– Chief Medical Officer and Senior Vice President of Drug Development
Dr. Atul Mahableshwarkar is a board-certified adult psychiatrist with two decades of drug development experience. He oversees all scientific and regulatory matters associated with new product development, approval, and maintenance, and leads Drug Development, Clinical Affairs and Operations, and Pharmacovigilance. Dr. Mahableshwarkar is responsible for advancing therapeutic candidates from pre-investigational new drug application enabling studies through all phases of clinical trials.
Prior to joining Emalex, he served as Vice President of Clinical Development at Revance Therapeutics and BlackThorn Therapeutics, Senior Medical Director at Takeda Development Center Americas, and Director of Clinical Development at GlaxoSmithKline and Janssen Pharmaceuticals. Dr. Mahableshwarkar has designed and conducted global clinical trials in Alzheimer’s disease, anxiety disorders, bipolar disorder, major depression, Parkinson’s Disease and schizophrenia. His most recent efforts led to the FDA approval of Trintellix® (vortioxetine), a serotonin modulator, for the treatment of major depressive disorder.
Formerly, he was an Associate Professor and Vice Chair of the Department of Psychiatry and Behavioral Sciences at the Chicago Medical School of Rosalind Franklin University of Health Sciences. He also led behavioral health services at the former North Chicago VA Medical Center, providing care to patients with psychiatric disorders.
Dr. Mahableshwarkar is a founding member of the International Society for CNS Clinical Trials and Methodology and the CNS Summit. He is a graduate of the Armed Forces Medical College in India and completed a residency in adult psychiatry and a fellowship in neuropsychiatry at the Chicago Medical School of Rosalind Franklin University of Health Sciences.